Plasma cell myeloma is the second most common haematological malignancy. The therapy in this disease has changed dramatically in recent twenty years due to new drugs implementation such as proteasome inhibitors and immunomodulatory drugs. Scientists’ efforts made to better cognition of normal immune surveillance in myeloma led to the formulation of new treatment strategy including immune system involvement. Many of these therapies are being evaluated in clinical trials and the preliminary results are promising. Probably another time in the last year’s we may witness paradigm revision in the plasma cell myeloma therapy. In the article we present essential, in our opinion, immunotherapy methods in myeloma.